Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
CF Industries Poised to See Improving Operations, RBC Says

CF Industries Poised to See Improving Operations, RBC Says

MT newswireMT newswire2026/11/09 17:02
01:02 PM EST, 11/09/2026 (MT Newswires) -- CF Industries (CF) is set to improve operations into 2027 with Yazoo City restarting and nitrogen fundamentals expected to be stronger near-term, RBC Capital Markets said in a note Sunday. "We expect relatively strong demand, with ongoing Indian tenders, Brazil import catch-up, and the US Spring season while corn prices remain supportive for nitrogen applications," it said. On the supply side, the report pointed to prolonged restricted supply from the Middle East, high global nitrogen marginal costs, and a seasonal wind-down of Chinese exports. Additionally, the company's Yazoo City operations are expected to resume in H1 of 2027, while early construction at Blue Point One is progressing well, the note said. The report also said CF is expected to deliver solid cash generation even after capital expenditure spend on the Blue Point project, backing its continued share buybacks. "We are positive long-term on CF's fundamentals, but see near-term US/Iran war headline risk to shares," it said. RBC raised its price target to $125 from $115 and kept a sector perform rating. Price: 120.32, Change: +0.93, Percent Change: +0.78
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12